Clinical trial · Observational
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
A Prospective Study for Pleural Lavage Cytology in Patients With Esophageal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis. Pleural lavage cytology (PLC) is reported to be associated with disease recurrence and patient survival in lung cancer, but the value is unclear in esophageal cancer. The aim of this study is to evaluate the value of PLC in esophageal cancer patient in terms of frequencies, association with patient survival, and efficacy of postoperative treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pleural lavage | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- number of patients who had positive pleural lavage cytology
- timeFrame
- July 2022 to July 2023
- description
- Frequency of positive pleural lavage cytology in resectable esophageal squamous cell carcinoma
Secondary outcomes (1)
- measure
- Time period from date of surgery to the date of death
- timeFrame
- July 2022 to July 2026
- description
- value of pleural lavage cytology in predict patient survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * esophageal cancer with histological confirmation before treatment. * resectable esophageal cancer with clinical T1-4a/N0-3/M0 staging * potential R0 resection * no history of other malignancies Exclusion Criteria: * severe major organ dysfunction (American society of anesthesiologisits score \>3 ) * patients underwent ESD or EMR * pleural lavage is unavailable due to adhesions
References
Publications (0)
Data not yet available